We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News COVID-19 AACC 2021 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology BioResearch Industry

BIOHIT  Healthcare OY

ZEUS Receives FDA EUA Approval for SARS-SoV-2 Tests on Dynex Instruments

By LabMedica International staff writers
Posted on 13 Sep 2021
ZEUS Scientific (Branchburg, NJ, USA) has received FDA authorization to run the ZEUS ELISA SARS-SoV-2 Total Antibody Test System using the Dynex Agility, Dynex DSX or Dynex DS2 Automated ELISA Systems from Dynex Technologies (Chantilly, VA, USA).

The ZEUS ELISA SARS-CoV-2 IgG Test System assay utilizes a dual antigen combination of recombinant S1 receptor binding domain (RBD) viral protein and recombinant nucleoprotein that detects immune responses that other antibody tests may miss.

Illustration
Illustration

The SARS-CoV-2 IgG Test system was first granted EUA in October of 2020 to run the ZEUS SARS-CoV-2 IgG Test System manually or using the Dynex Agility Automated ELISA System. The FDA has extended the EUA to include the Dynex DS2 and Dynex DSX automated ELISA systems.

Related Links:
ZEUS Scientific
Dynex Technologies




AACC

Latest COVID-19 News



SEROSEP